Xilio Therapeutics, Inc.

As of August 8, 2024, Xilio Therapeutics, Inc. is considered risky and overvalued due to a high Price to Book Value of 3.39, a low EV to EBIT of 0.91, a troubling ROE of -507.61%, and significant underperformance with a year-to-date return of -20.06% compared to the S&P 500's 12.22%.

As of August 8, 2024, Xilio Therapeutics, Inc. is rated as risky and overvalued due to concerning financial metrics, including a Price to Book Value of 3.39 and a negative EV to Sales ratio of -5.56, while its stock has underperformed the S&P 500 with a year-to-date return of -29.84%.

As of May 13, 2025, Xilio Therapeutics, Inc. shows a mildly bearish trend due to bearish signals from the weekly MACD and daily moving averages, despite some potential for recovery indicated by the monthly MACD and Dow Theory.

Xilio Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $3 million and a net loss of $13 million as of March 2025. The company has a market cap of $34.44 million and does not pay dividends.

As of Jun 18, Xilio Therapeutics, Inc. has a market capitalization of 34.44 million and reported net sales of 9.27 million with a net profit of -54.31 million over the last four quarters.